Testing a simpler treatment for immune-mediated TTP
Part of Blood & lymphatic clinical trials.
This study is testing a new combination of medicines—immune-suppressing drugs, caplacizumab, and plasma infusions—to treat immune-mediated TTP without standard plasma exchange. It aims to make treatment simpler and potentially safer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of TTP (immune TTP) based on standard blood tests, with low platelets (≤30) and kidney markers not too high (creatinine ≤200).
- You are not already doing well (platelets over 100) before starting plasma treatment.
- You do not have other serious conditions like active cancer, uncontrolled HIV, or another cause for blood problems.
- You are not pregnant, breastfeeding, or planning pregnancy soon, and if you could become pregnant you use effective birth control and have a negative pregnancy test.
- You weigh 100 kg (about 220 lbs) or less, and you don't have major bleeding risks or need blood thinners that can't be paused.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks back at medical records of people with immune-mediated thrombotic thrombocytopenic purpura (TTP), a rare blood clotting disorder. It aims to better understand the disease and how it is treated.
This study tests a new medicine called TGD001 for people with a group of rare blood disorders called thrombotic microangiopathies (TMAs), where small blood clots form and damage organs. The goal is to see if TGD001 can help stop the clotting and improve outcomes.
This trial is looking at the immune system's role in thrombotic thrombocytopenic purpura (TTP), a rare blood disorder. It may help researchers understand the condition better and possibly improve future treatments.
This trial tests whether taking aspirin daily can help prevent the blood-clotting episodes (called TTP) caused by a severe lack of a specific protein in your blood. If you have a history of TTP or a genetic form that increases your risk, this study may help reduce those dangerous episodes.
This study reviews medical records of people with a rare blood clotting disorder called cTTP who received a treatment called rADAMTS13 through an early access program. The goal is to learn more about how the treatment works in real life.
This study tests a drug called efgartigimod to see if it can prevent relapses in people with immune-mediated thrombotic thrombocytopenic purpura (iTTP) who are currently in remission. It may help by reducing the immune activity that causes the condition.
Hear when a new Thrombotic Microangiopathies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.